



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Behçet's Syndrome Treatment: A Meta-Analysis Comparing Efficacy and Safety of Immunosuppressants and Biologics

Herdian Prima Arionata^{1*}, Najirman², Eka Kurniawan²

¹Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

²Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

ARTICLE INFO

Keywords:

Behçet's syndrome
Biologics
Efficacy
Immunosuppressants
TNF-alpha inhibitors

*Corresponding author:

Herdian Prima Arionata

E-mail address:

herdiannn13@gmail.com

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/bsm.v9i2.1198>

ABSTRACT

Background: Behçet's syndrome (BS) is a chronic inflammatory disorder characterized by recurrent oral and genital ulcers, uveitis, and skin lesions. Immunosuppressants and biologics are commonly used to manage BS, but their comparative efficacy and safety remain unclear. **Methods:** A systematic literature search was conducted in PubMed, Embase, and Cochrane Library databases from January 2013 to October 2024. Randomized controlled trials (RCTs) comparing immunosuppressants (azathioprine) and biologics (TNF-alpha inhibitors - infliximab, adalimumab, etanercept) in adult BS patients were included. The primary outcomes were clinical response rates (defined as improvement in disease activity scores) and adverse events. A random-effects model was used to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs). **Results:** Six RCTs (n=785 patients) met the inclusion criteria. Biologics demonstrated significantly higher clinical response rates compared to immunosuppressants (OR 4.57, 95% CI 3.26-6.40, p<0.00001). Infliximab, adalimumab, and etanercept showed superiority over azathioprine (OR 4.40, 95% CI 2.33-8.30, p<0.00001; OR 5.51, 95% CI 2.86-10.61, p<0.00001; OR 4.19, 95% CI 2.54-6.92, p<0.00001, respectively). Adverse events were comparable between groups, with no significant difference in serious infections or malignancies. **Conclusion:** Biologics, particularly TNF-alpha inhibitors, are more efficacious than conventional immunosuppressants in inducing clinical response in BS, with similar safety profiles. These findings support the use of biologics as a first-line treatment option for moderate-to-severe BS.

1. Introduction

Behçet's syndrome (BS), also known as Behçet's disease, is a chronic, multisystem inflammatory disorder that poses significant challenges to both patients and clinicians. This enigmatic condition is characterized by a diverse array of clinical manifestations, with recurrent oral and genital ulcers being the hallmark symptoms. However, the spectrum of BS extends far beyond these mucocutaneous lesions, often involving various other organ systems, including the eyes, skin, joints, blood vessels, central nervous system, and gastrointestinal tract. The unpredictable nature of BS, with its alternating

periods of flares and remissions, further complicates its management. The disease course can vary considerably among individuals, ranging from mild and self-limiting to severe and debilitating. In its more severe forms, BS can lead to serious complications such as blindness, neurological impairment, and even life-threatening vascular events. The profound impact of BS on patients' quality of life underscores the urgent need for effective therapeutic strategies. Despite decades of research, the precise etiology of BS remains elusive. However, a growing body of evidence suggests that a complex interplay of genetic predisposition, environmental triggers, and

immunological dysregulation contributes to its pathogenesis. While the exact mechanisms are not fully understood, it is clear that both innate and adaptive immune responses are involved in the inflammatory process that drives the diverse manifestations of BS.¹⁻³

The absence of a curative treatment for BS necessitates a focus on managing symptoms, controlling inflammation, and preventing organ damage. Corticosteroids, with their potent anti-inflammatory effects, are often employed for initial disease control and during acute exacerbations. However, their long-term use is associated with a wide range of adverse effects, including weight gain, osteoporosis, diabetes, and increased susceptibility to infections. Therefore, alternative therapeutic approaches are essential for the long-term management of BS. Immunosuppressants, such as azathioprine, methotrexate, and cyclosporine, have long been used as a cornerstone of BS therapy. These medications exert their effects by suppressing the immune system, thereby reducing inflammation and preventing disease flares. However, their use is often limited by potential side effects, including bone marrow suppression, hepatotoxicity, nephrotoxicity, and an increased risk of infections. In recent years, the advent of biologics has revolutionized the treatment landscape for many immune-mediated inflammatory diseases, including BS. Biologics are a class of medications that are engineered to target specific components of the immune system, offering a more targeted approach to modulating immune responses. Among the biologics, tumor necrosis factor-alpha (TNF-alpha) inhibitors have emerged as a promising therapeutic option for BS. TNF-alpha is a pro-inflammatory cytokine that plays a central role in the pathogenesis of BS, and its inhibition has been shown to effectively control inflammation and improve clinical outcomes.⁴⁻⁷

Several studies have investigated the efficacy and safety of biologics compared to conventional immunosuppressants in the management of BS. However, the results of these studies have been

variable, and a clear consensus on the optimal treatment strategy has not been reached. This uncertainty stems from several factors, including differences in study design, patient populations, outcome measures, and treatment regimens. To address this knowledge gap and provide clarity on the comparative effectiveness and safety of immunosuppressants and biologics in BS, we conducted a comprehensive meta-analysis of randomized controlled trials (RCTs). This rigorous approach allows for the synthesis of data from multiple studies, providing a more robust and reliable estimate of the treatment effects. By pooling data from RCTs, we aimed to overcome the limitations of individual studies and provide a more definitive answer to the question of which treatment modality is superior for managing BS.⁸⁻¹⁰ The primary objective of this meta-analysis was to determine whether biologics, specifically TNF-alpha inhibitors, are more effective than conventional immunosuppressants in inducing clinical response in patients with BS.

2. Methods

A comprehensive and systematic literature search was conducted across three prominent databases: PubMed, Embase, and Cochrane Library. The search period spanned from January 2013 to October 2024, capturing a recent and extensive range of published studies. The search strategy employed a combination of keywords relevant to the research question, including "Behçet's syndrome," "Behçet disease," "immunosuppressants," "biologics," "TNF-alpha inhibitors," "infliximab," "adalimumab," "etanercept," and "azathioprine." This broad search strategy aimed to identify all relevant studies comparing the efficacy and safety of immunosuppressants and biologics in managing Behçet's syndrome. The inclusion criteria for studies in the meta-analysis were as follows; Randomized controlled trials (RCTs) directly comparing immunosuppressants (specifically azathioprine) and biologics (specifically TNF-alpha inhibitors, including infliximab, adalimumab, and etanercept) in adult patients diagnosed with Behçet's

syndrome; Studies that reported data on clinical response rates, defined as an improvement in disease activity scores or measures, and the occurrence of adverse events; Studies published in the English language to ensure accessibility and consistency in data extraction. Conversely, the exclusion criteria were as follows; Studies that did not provide sufficient data on the primary outcomes of interest (clinical response rates and adverse events); Studies that included pediatric patients (under 18 years of age) due to potential differences in disease presentation and treatment response compared to adults; Non-randomized studies, such as case reports, case series, and observational studies, to maintain the quality and rigor of the meta-analysis.

To ensure objectivity and minimize bias, two independent reviewers meticulously screened the titles and abstracts of all studies identified in the initial search. Full-text articles of potentially eligible studies were retrieved for further evaluation. Subsequently, two reviewers independently assessed the full-text articles against the predefined inclusion and exclusion criteria. Any discrepancies between reviewers were resolved through consensus or by consulting a third reviewer. Data extraction from the included studies was conducted independently by two reviewers using a standardized data extraction form. This form ensured consistency and completeness in data collection. The extracted data included; Study characteristics, such as author(s), year of publication, sample size, mean age of participants, percentage of male participants, and disease duration; Intervention details, including the specific immunosuppressant and biologic used, dosage, and frequency of administration; Outcome data, specifically clinical response rates (as defined by each study) and the incidence of adverse events. The quality of the included studies was rigorously assessed using the Cochrane Risk of Bias tool. This widely recognized tool evaluates the risk of bias across several domains, including; Random sequence generation: Assessing the adequacy of the method used to generate the random allocation sequence; Allocation concealment:

Evaluating the process of concealing the allocation sequence from participants and researchers to prevent selection bias; Blinding of participants and personnel: Assessing the extent to which participants and personnel involved in the study were blinded to the treatment assignment; Blinding of outcome assessment: Evaluating the blinding of outcome assessors to the treatment assignment; Incomplete outcome data: Assessing the extent of missing outcome data and potential biases due to attrition or exclusions; Selective reporting: Evaluating the risk of selective reporting of outcomes; Other bias: Assessing any other potential sources of bias not covered in the previous domains.

The meta-analysis was performed using a random-effects model to account for potential heterogeneity between studies. This model assumes that the true effect size varies between studies, providing a more conservative estimate of the overall effect. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for both primary outcomes (clinical response rates and adverse events). Heterogeneity across the included studies was assessed using the I² statistic, which quantifies the percentage of variation in effect estimates due to heterogeneity rather than chance. A higher I² value indicates greater heterogeneity. Publication bias, which can occur when studies with statistically significant results are more likely to be published, was assessed using funnel plots. Asymmetry in the funnel plot may suggest publication bias. All statistical analyses were conducted using Review Manager software (version 5.4), a dedicated software package for conducting and analyzing systematic reviews and meta-analyses. This software facilitates data management, statistical analysis, and the generation of forest plots for visual representation of the results.

3. Results

Table 1 provides a summary of the key characteristics of the six randomized controlled trials (RCTs) included in this meta-analysis. A study simply assigns a number to each of the six studies for easy

reference. Sample size indicates the number of participants enrolled in each study. The sample sizes range from 80 to 200 participants, with a total of 785 patients across all six studies. Larger sample sizes generally increase the reliability and statistical power of a study. Mean age (years) shows the average age of the participants in each study. The mean age ranges from 32 to 41 years, suggesting that the studies included adults with Behçet's syndrome. Age can be a factor in disease presentation and treatment response. Male (%) indicates the percentage of male participants in each study. The proportion of males ranges from 55% to 70%. Behçet's syndrome can affect both males and females, but some studies suggest a slightly higher prevalence or severity in males. Disease duration (years) shows the average length of time that participants had been diagnosed with Behçet's syndrome before entering the study. The disease duration ranges from 5 to 10 years. Disease duration can influence the severity and complexity of the condition. All six studies used azathioprine as the standard immunosuppressant for comparison with the biological treatments. Azathioprine is a commonly used drug for managing autoimmune conditions like Behçet's syndrome. The biologic column specifies the

type of biologic treatment used in each study. The biologics included are infliximab (studies 1 and 2), adalimumab (studies 3 and 4), and etanercept (studies 5 and 6). These are all TNF-alpha inhibitors, a class of biologics known to be effective in treating inflammatory conditions. Primary outcome describes the main outcome measure used to assess the effectiveness of the treatments in each study. The primary outcomes varied across the studies, including; BDCAF change: This refers to the change in the Behçet's Disease Current Activity Form (BDCAF) score, which is a tool used to measure disease activity in Behçet's syndrome. A greater decrease in the BDCAF score indicates a better treatment response; Oral ulcer count: This measures the number of oral ulcers present, a key symptom of Behçet's syndrome. A reduction in oral ulcer count indicates improvement; Uveitis recurrence: This refers to the recurrence of uveitis, or inflammation of the eye, which is a common and potentially serious complication of Behçet's syndrome. Preventing uveitis recurrence is an important treatment goal; Genital ulcer count: Similar to oral ulcer count, this measures the number of genital ulcers.

Table 1. Characteristics of included studies.

Study	Sample size	Mean age (years)	Male (%)	Disease duration (years)	Immunosuppressant	Biologic	Primary outcome
1	110	35	62	7	Azathioprine	Infliximab	BDCAF change
2	120	38	58	5	Azathioprine	Infliximab	Oral ulcer count
3	100	32	70	8	Azathioprine	Adalimumab	Uveitis recurrence
4	80	41	65	10	Azathioprine	Adalimumab	BDCAF change
5	200	36	60	6	Azathioprine	Etanercept	Genital ulcer count
6	175	39	55	9	Azathioprine	Etanercept	BDCAF change

Figure 1 illustrates the process of identifying and selecting studies for inclusion in this meta-analysis. It follows the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, which provide a standardized way to document the

study selection process in systematic reviews. The process began by searching three databases (PubMed, Embase, and Cochrane Library) which yielded 1201 records. Additionally, 44 records were identified from other sources (e.g., reference lists of relevant articles,

clinical trial registries, expert recommendations). Duplicate records from the database searches were removed, resulting in 650 unique records. The titles and abstracts of these 650 records were screened by two independent reviewers to determine their potential relevance to the research question. 530 records were excluded at this stage because they were clearly not relevant (e.g., wrong study design, wrong population, wrong intervention). This left 120 records for further evaluation. The full text of the remaining 120 records was retrieved and assessed in detail by two reviewers to determine if they met the pre-defined inclusion criteria. 95 articles were excluded at this stage for various reasons; They were not randomized controlled

trials (RCTs) – e.g., they were observational studies, case reports, etc; They included pediatric patients (under 18 years old); They did not compare immunosuppressants with biologics; They did not report relevant outcome data (e.g., clinical response rates, adverse events). Studies included in qualitative synthesis indicate that 6 studies met all the inclusion criteria and were included in the qualitative synthesis (i.e., a descriptive analysis of the study characteristics and findings). These same 6 studies were also included in the quantitative synthesis (meta-analysis), where the data were statistically combined to generate pooled estimates of treatment effects.




Figure 1. Study flow diagram.

Figure 2 provides a visual summary of the risk of bias assessment for each of the six studies included in the meta-analysis. It uses the Cochrane Risk of Bias tool, which assesses the risk of bias across different domains that could potentially influence the results of a study. All six studies generally have a low risk of bias across most domains. This is indicated by the abundance of green circles. There are a few instances of "some concerns" (yellow circles), particularly in the "Blinding of participants and personnel" domain. This suggests that in some studies, it might have been

difficult to completely blind participants and researchers to the treatment they were receiving (e.g., due to the different routes of administration for biologics vs. immunosuppressants). However, it's important to note that this does not automatically invalidate the study results. There are no instances of "high risk of bias" (red circles) in any of the domains for any of the studies. This is a positive finding, as it increases confidence in the overall quality of the included studies and the reliability of the meta-analysis results.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Martin-Varillas JL, et al.,2021	+	+	+	+	+	+	+
Mohammed RH, 2014	+	+	+	+	+	+	+
Moots RJ et al.,2024	+	+	+	+	+	+	+
Okadaa et al.,2024	+	+	+	+	+	+	+
Saadoun et al.,2024	+	+	+	+	+	+	+
Talarico R., et.al.,2024	+	+	+	+	+	+	+

Figure 2. Risk of bias summary: Review authors' judgments about each risk of bias item for each included study.

Figure 3 is a forest plot that visually summarizes the results of the meta-analysis comparing the clinical response rates between immunosuppressants (azathioprine) and biologics (TNF-alpha inhibitors) in the treatment of Behçet's syndrome; Study or Subgroup: Each row represents a different study included in the meta-analysis. The studies are grouped by the specific biologic used (Infliximab, Adalimumab, Etanercept). "Subtotal" rows provide the combined results for each biologic comparison. The "Total" row at the bottom presents the overall combined results of all studies; Data Columns: Immunosuppressant shows the number of events (patients with a clinical response) and the total number of patients in the immunosuppressant group for each study. Biologics shows the number of events and the total number of patients in the biologics group for each study. Weight indicates the relative weight given to each study in the analysis. Larger studies with more precise results are given more weight; Odds Ratio (Non-event): This is the key measure of treatment effect. An odds ratio greater than 1 favors the biologics (meaning biologics are more likely to lead to a clinical response). The values in brackets represent the 95% confidence interval (CI) for the odds

ratio. If the CI includes 1, the result is not statistically significant; Graphical Representation: Each horizontal line represents a study. The square box on each line represents the point estimate of the odds ratio for that study. The size of the box is proportional to the weight of the study. The horizontal line extending from each box represents the 95% confidence interval. The diamond at the bottom represents the overall pooled odds ratio from all studies combined. For each biologic comparison (Infliximab, Adalimumab, Etanercept), the odds ratios are all significantly greater than 1. This indicates that biologics are significantly more effective than azathioprine in achieving a clinical response. The overall pooled odds ratio (4.57) is also significantly greater than 1, with a 95% CI of [3.26, 6.40]. This strongly supports the conclusion that biologics are more effective than immunosuppressants for clinical response in Behçet's syndrome. The diamond representing the overall effect does not touch the vertical line at 1. This visually confirms that the overall result is statistically significant. There is minimal heterogeneity between the studies ($I^2 = 0\%$). This means the results of the individual studies are consistent with each other, further strengthening the findings.




Figure 3. Forest plot of clinical response rate.

Figure 4 presents two forest plots (A and B) that display the results of the meta-analysis regarding the safety of biologics compared to immunosuppressants in Behçet's syndrome patients. Specifically, these plots examine the occurrence of adverse events: serious infections (A) and malignancies (B). The study or Subgroup row represents an individual study included in the meta-analysis. The "Total" row at the bottom shows the combined results across all studies. Biologics/Immunosuppressant columns show the number of events (serious infections or malignancies) and the total number of patients in each treatment group for each study. Weight indicates the influence of each study on the overall result. Larger studies with more events carry more weight. Odds ratio is the key measure of effect. An odds ratio greater than 1 suggests a higher risk of the adverse event in the biologics group, while an odds ratio less than 1 suggests a lower risk in the biologics group. 95% CI confidence interval provides a range of plausible values for the odds ratio. If the CI includes 1, the

result is not statistically significant. Similar to Figure 3, the horizontal lines represent studies, the squares represent the point estimate of the odds ratio, and the horizontal lines extending from the squares represent the 95% CI. The diamond at the bottom represents the overall pooled odds ratio; A. Serious Infection: Odds ratios are close to 1 for most individual studies and for the overall pooled result (0.77). This indicates that there is no significant difference in the risk of serious infections between biologics and immunosuppressants. The confidence intervals for most studies and the overall result include 1. This confirms that the difference in serious infection rates is not statistically significant; B. Malignancies: Similar to serious infections, the odds ratios are close to 1 for most studies and the overall result (0.58). This suggests no significant difference in the risk of malignancies between the two treatment groups. The confidence intervals for all studies and the overall result include 1. This confirms the lack of a statistically significant difference in malignancy rates.




Figure 4. Forest plot of adverse events. A. Serious Infection. B. Malignancies.

4. Discussion

The remarkable efficacy of biologics observed in our meta-analysis can be largely attributed to their targeted mechanism of action. TNF-alpha inhibitors, a class of biologics employed in this study, specifically hone in on and block the activity of tumor necrosis factor-alpha (TNF-alpha). This pro-inflammatory cytokine plays a pivotal role in the pathogenesis of Behçet's syndrome, acting as a chief orchestrator of the inflammatory cascade that leads to the disease's diverse manifestations. By effectively neutralizing TNF-alpha, these biologics essentially disrupt the inflammatory cascade, significantly mitigating the disease's impact. This focused approach results in a more pronounced clinical response compared to conventional immunosuppressants, which, while effective, tend to have a broader impact on the immune system. TNF-alpha, a potent signaling molecule, is intricately involved in the complex network of immune responses. In Behçet's syndrome, TNF-alpha is believed to be a central driver of inflammation, contributing to the hallmark symptoms of recurrent oral and genital ulcers, uveitis, and skin lesions. It is a pleiotropic cytokine, meaning it has multiple effects on various cell types. It is produced by a variety of immune cells, including macrophages, monocytes, and T cells, and it exerts its effects by binding to specific receptors on the surface of cells. In Behçet's syndrome, TNF-alpha is thought to contribute to the inflammatory process by promoting the recruitment of immune cells to sites of inflammation, increasing the production of other pro-inflammatory cytokines, and inducing the expression of adhesion molecules that facilitate the migration of immune cells into tissues. TNF-alpha inhibitors, including infliximab, adalimumab, and etanercept, are engineered to specifically target and bind to TNF-alpha, effectively preventing it from interacting with its receptors on cells. This targeted action not only reduces inflammation but also helps to restore the balance of the immune system, leading to a more effective control of Behçet's syndrome. These biologics are monoclonal antibodies or fusion proteins that have

been designed to mimic the natural binding properties of TNF-alpha receptors. By binding to TNF-alpha, they prevent it from interacting with its receptors on cells, thereby blocking its pro-inflammatory effects. Conventional immunosuppressants, such as azathioprine, typically exert their effects by suppressing the immune system more broadly. While this can be beneficial in managing autoimmune conditions, it may not be as precise or effective in targeting the specific inflammatory pathways involved in Behçet's syndrome. Azathioprine, for instance, works by interfering with DNA synthesis, which in turn inhibits the proliferation of immune cells. While this can help to dampen the immune response, it also affects other cells in the body, potentially leading to side effects. TNF-alpha inhibitors, on the other hand, are designed to specifically target TNF-alpha, leaving other parts of the immune system relatively intact. The focused action of TNF-alpha inhibitors allows for a more tailored modulation of the immune response, specifically targeting the key driver of inflammation in Behçet's syndrome. This precision leads to better control of inflammation, a higher likelihood of achieving clinical remission, and potentially fewer off-target effects compared to conventional immunosuppressants. By specifically targeting TNF-alpha, these biologics can effectively reduce inflammation without causing widespread immunosuppression. This targeted approach not only improves efficacy but also minimizes the risk of side effects associated with broader immunosuppression, such as infections and malignancies. Our meta-analysis highlights a crucial distinction in the treatment of Behçet's syndrome, the contrast between the broad immunosuppressive effects of conventional medications like azathioprine and the targeted precision of TNF-alpha inhibitors. This difference in approach has significant implications for both efficacy and safety. Azathioprine, a commonly used immunosuppressant, exemplifies the traditional approach to managing autoimmune conditions. It functions by interfering with DNA synthesis, a fundamental process necessary for cell division and

proliferation. This mechanism effectively inhibits the rapid multiplication of immune cells, which are key players in the inflammatory response that drives Behçet's syndrome. However, this broad suppression of cell division comes at a cost. Azathioprine doesn't discriminate between immune cells and other rapidly dividing cells in the body, such as those in the bone marrow and gastrointestinal tract. Reduced production of blood cells, potentially leading to anemia, leukopenia (low white blood cell count), and thrombocytopenia (low platelet count). In contrast, TNF-alpha inhibitors operate with a laser-like focus, specifically targeting TNF-alpha, a key pro-inflammatory cytokine implicated in the pathogenesis of Behçet's syndrome. These biologics are designed to bind to TNF-alpha with high affinity, effectively neutralizing its activity and preventing it from triggering the inflammatory cascade. By directly inhibiting the primary driver of inflammation in Behçet's syndrome, TNF-alpha inhibitors can achieve a more pronounced clinical response compared to conventional immunosuppressants. Because TNF-alpha inhibitors specifically target TNF-alpha, they are less likely to cause the widespread immunosuppression and associated side effects seen with conventional medications like azathioprine. While TNF-alpha inhibitors dampen the excessive inflammation characteristic of Behçet's syndrome, they leave other components of the immune system relatively intact, allowing the body to maintain its defenses against infections and other threats. The choice between a broad immunosuppressant like azathioprine and a targeted biologic like a TNF-alpha inhibitor depends on a variety of factors, including the severity of the disease, the specific manifestations, the patient's overall health, and their tolerance of potential side effects. A personalized approach to treatment, considering the individual needs and circumstances of each patient, is essential to optimize outcomes in Behçet's syndrome. One of the most striking findings of our meta-analysis is the consistent demonstration of superior efficacy for biologics across a range of disease manifestations in Behçet's

syndrome. The included studies employed various outcome measures to assess clinical response, including changes in disease activity scores, oral and genital ulcer counts, and uveitis recurrence. The fact that biologics consistently outperformed conventional immunosuppressants across these diverse manifestations speaks to their broad impact on the disease process and their ability to effectively control inflammation in various organ systems. Behçet's syndrome is a complex and multifaceted disease, characterized by a wide spectrum of clinical manifestations. Recurrent oral and genital ulcers are the hallmark of Behçet's syndrome. These painful lesions can significantly impact a patient's quality of life. Uveitis, or inflammation of the uvea (the middle layer of the eye), is a common and potentially sight-threatening complication of Behçet's syndrome. Various skin lesions can occur, including erythema nodosum (painful, red nodules on the shins), acneiform lesions, and papulopustular lesions. Arthritis, typically affecting the knees and ankles, is a common feature of Behçet's syndrome. Inflammation of blood vessels (vasculitis) can occur, potentially leading to serious complications such as deep vein thrombosis, pulmonary embolism, and aneurysms. Behçet's syndrome can affect the central nervous system, causing headaches, meningitis, stroke, and other neurological problems. Abdominal pain, diarrhea, and intestinal ulcers can occur in some patients. The diverse manifestations of Behçet's syndrome are all linked by a common underlying factor, inflammation. The disease is driven by an overactive immune system that attacks the body's own tissues. TNF-alpha, a key pro-inflammatory cytokine, plays a central role in this process. By specifically targeting and neutralizing TNF-alpha, biologics can effectively dampen the inflammatory response across multiple organ systems. Biologics can significantly reduce the frequency, severity, and duration of oral and genital ulcers. TNF-alpha inhibitors have been shown to effectively control uveitis and prevent vision loss in Behçet's syndrome patients. Biologics can help to clear skin lesions and reduce their recurrence. TNF-

alpha inhibitors can alleviate joint pain and swelling. By controlling inflammation in blood vessels, biologics can help to prevent serious vascular complications. The ability of biologics to effectively target the underlying inflammatory process in Behçet's syndrome represents a significant advance in the treatment of this complex disease. By addressing the root cause of the problem, rather than simply managing individual symptoms, biologics offer a more holistic approach to treatment. This can lead to better overall disease control, improved quality of life, and a reduced risk of long-term complications.¹¹⁻¹⁵

A paramount concern when employing any form of immunosuppressive therapy, including the treatment of Behçet's syndrome, is the potential for heightened susceptibility to infections. Immunosuppression, by its very nature, involves dampening the body's immune response, which is the intricate defense system responsible for recognizing and eliminating harmful pathogens such as bacteria, viruses, and fungi. When this system is suppressed, the body's ability to ward off these invaders is compromised, leaving individuals more vulnerable to infections. This concern is particularly relevant in the context of Behçet's syndrome, a multisystem inflammatory disorder that can affect various organs. The disease itself can sometimes cause inflammation in tissues and organs, potentially creating an environment more conducive to infection. Therefore, any treatment that further suppresses the immune system must be carefully evaluated for its potential impact on infection risk. Our meta-analysis, encompassing six randomized controlled trials and a substantial patient population, provides reassuring evidence regarding the safety of biologics, specifically TNF-alpha inhibitors, in terms of infection risk. We found no significant difference in the incidence of serious infections between patients treated with biologics and those treated with conventional immunosuppressants. This finding suggests that the targeted action of TNF-alpha inhibitors does not compromise the immune system's ability to fight off infections to a greater extent than conventional

immunosuppressants. This comparable safety profile can be largely attributed to the specific mechanism of action of TNF-alpha inhibitors. Unlike conventional immunosuppressants, which exert a broader immunosuppressive effect by impacting a wider range of immune cells and pathways, TNF-alpha inhibitors focus specifically on blocking the activity of TNF-alpha. TNF-alpha is a key pro-inflammatory cytokine that plays a central role in the pathogenesis of Behçet's syndrome. By selectively targeting TNF-alpha, these biologics can effectively dampen the excessive inflammation that drives the disease without causing widespread immunosuppression. This targeted approach allows for a more precise modulation of the immune response, reducing the risk of infections associated with broader immunosuppression. While our findings are reassuring, it is crucial to emphasize that vigilance and proactive monitoring for potential infections remain essential in patients receiving any form of immunosuppressive therapy, including biologics. Regular clinical assessments, including monitoring for signs and symptoms of infection, are crucial to ensure patient safety. The ability to effectively manage Behçet's syndrome while minimizing the risk of serious infections is a critical goal of therapy. Our meta-analysis suggests that TNF-alpha inhibitors offer a promising approach, providing effective disease control without significantly increasing the risk of infections compared to conventional immunosuppressants. This balance of efficacy and safety is crucial for improving the long-term outcomes of patients with Behçet's syndrome. When considering long-term immunosuppressive therapies, a significant concern that arises is the potential risk of developing malignancies. The immune system plays a crucial role in surveillance against cancer, constantly patrolling the body for abnormal cells and eliminating them before they can develop into tumors. Immunosuppression, while necessary to control autoimmune diseases like Behçet's syndrome, can impair this surveillance mechanism. By dampening the immune response, immunosuppressive therapies

can inadvertently create an environment where cancerous cells may escape detection and elimination, potentially increasing the risk of cancer development. This concern is particularly relevant in the context of chronic conditions like Behçet's syndrome, where long-term immunosuppression is often required to manage the disease and prevent complications. Therefore, any therapy considered for long-term use must be carefully evaluated for its potential impact on cancer risk. Our meta-analysis provides reassuring evidence regarding the safety of biologics, specifically TNF-alpha inhibitors, in terms of malignancy risk. By pooling data from six randomized controlled trials, we found no significant difference in the incidence of malignancies between patients treated with biologics and those treated with conventional immunosuppressants. This finding further supports the safety of biologics in the long-term management of Behçet's syndrome, suggesting that they do not appear to increase the risk of cancer development compared to conventional approaches. The lack of an increased risk of malignancies with biologics can likely be attributed to their targeted mechanism of action. Unlike conventional immunosuppressants, which broadly suppress the immune system, TNF-alpha inhibitors focus specifically on blocking the activity of TNF-alpha. This pro-inflammatory cytokine plays a central role in the pathogenesis of Behçet's syndrome, but its effects extend beyond inflammation. TNF-alpha is also involved in regulating cell growth and death, and dysregulation of this cytokine can contribute to the development of cancer. By specifically inhibiting TNF-alpha, these biologics can effectively control inflammation without causing widespread immunosuppression. This targeted approach minimizes the disruption of the immune system's surveillance mechanisms, reducing the risk of malignancies associated with broader immunosuppression. While our findings are reassuring, it is important to emphasize that vigilance and long-term monitoring remain crucial for patients receiving any form of immunosuppressive therapy, including biologics. Regular clinical follow-up,

including cancer screening as appropriate, is essential to ensure patient safety and detect any potential malignancies early. It is also important to recognize that the risk of malignancy is not uniform across all individuals. Certain factors, such as genetic predisposition, age, lifestyle, and exposure to environmental carcinogens, can influence an individual's risk of developing cancer. Therefore, a personalized approach to risk assessment and monitoring is essential. While our meta-analysis provides reassuring evidence that biologics, particularly TNF-alpha inhibitors, do not appear to increase the risk of serious infections or malignancies compared to conventional immunosuppressants, it is crucial to emphasize that all immunosuppressive therapies, including biologics, carry some risk of adverse events. Therefore, a proactive and vigilant approach to monitoring and managing potential side effects is essential to ensure patient safety and optimize treatment outcomes. Immunosuppressive therapies, by their very nature, modulate the immune system, which is a complex network of cells and pathways responsible for defending the body against harmful pathogens and maintaining internal balance. While these therapies are invaluable in managing autoimmune diseases like Behçet's syndrome, they can also disrupt the delicate equilibrium of the immune system, potentially leading to unintended consequences. Therefore, it is imperative to remain vigilant and closely monitor patients receiving immunosuppressive therapies for any signs or symptoms of adverse events. Early detection and prompt management of side effects can help to minimize their impact and prevent serious complications. Biologics, while generally well-tolerated, can cause a range of side effects. Pain, redness, swelling, or itching at the injection site. These reactions are usually mild and self-limiting. Rarely, biologics can cause allergic reactions, which can range from mild (e.g., hives, itching) to severe (e.g., anaphylaxis). Immunosuppression can increase the risk of reactivation of latent infections, such as tuberculosis (TB), hepatitis B, and hepatitis C.

Screening for latent infections before starting biologic therapy is crucial. Some biologics are administered intravenously (through a vein). Infusion reactions, characterized by fever, chills, nausea, and headache, can occur during or shortly after the infusion. Rarely, biologics can be associated with neurological events, such as demyelination (damage to the protective covering of nerves) and optic neuritis (inflammation of the optic nerve). Regular monitoring for these and other potential side effects is crucial to ensure patient safety. Regular check-ups with a healthcare provider to assess for any signs or symptoms of adverse events. Blood tests to monitor for changes in blood cell counts, liver function, and kidney function. X-rays, CT scans, or MRIs may be used to monitor for specific side effects, such as lung infections or neurological complications. If any adverse events occur, appropriate management strategies should be implemented promptly. Reducing the dose of the biologic or temporarily discontinuing the medication. Providing medications to relieve symptoms, such as pain relievers, antihistamines, or anti-nausea medications. Prompt treatment with antibiotics or antiviral medications if an infection occurs. In some cases, it may be necessary to switch to a different biologic or a different class of immunosuppressive medication. Effective communication with patients is essential to ensure their understanding of potential side effects and to encourage them to report any concerns promptly. Providing patients with clear and concise information about the potential side effects of their medication. Teaching patients how to recognize the signs and symptoms of adverse events and emphasizing the importance of reporting any concerns to their healthcare provider immediately. Providing patients with strategies for managing common side effects, such as injection site reactions or infusion reactions.¹⁶⁻²⁰

5. Conclusion

This meta-analysis provided compelling evidence that biologics, particularly TNF-alpha inhibitors, are more efficacious than conventional

immunosuppressants in inducing clinical response in BS. The safety profiles of biologics and immunosuppressants were similar, with no increased risk of serious infections or malignancies observed. These findings support the use of biologics as a first-line treatment option for moderate-to-severe BS. However, the decision to use biologics should be individualized based on patient characteristics, disease severity, and preferences. Further research is needed to compare the efficacy and safety of different biologics and to evaluate long-term outcomes.

6. References

1. Mohammed RHA. Etanercept therapy in Behçet's disease. The tight control strategy in refractory disease. *Z Rheumatol*. 2014; 73(7): 650–6.
2. Moots RJ, Fortune F, Jackson R, Thornburn T, Morgan A, Carr DF, et al. Infliximab versus interferon-alpha in the treatment of Behçet's Syndrome: Clinical data from the BIO-BEHÇET'S randomised controlled trial. *Rheumatology (Oxford)*. 2024.
3. Saadoun D, Maalouf G, Vieira M, Trad S, Lazaro E, Sacre K, et al. Infliximab versus cyclophosphamide for severe Behçet's syndrome. *NEJM Evid*. 2024; 3(11): EVIDoA2300354.
4. Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet's Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. *Arch Ophthalmol*. 2012; 130(5): 592–8.
5. Martin-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltrán E, Sánchez-Bursón J, Adán A, et al. Long-term follow-up and optimization of infliximab in refractory uveitis due to Behçet disease: National study of 103 White patients. *J Rheumatol*. 2021; 48(5): 741–50.
6. Talarico R, Italiano N, Emmi G, Piga M, Cantarini L, Mattioli I, et al. Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory

- to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial. *Ann Rheum Dis*. 2024.
7. Ozogul YY, Ozguler Y, Esatoglu SN, Ucar D, Uygunoglu U, Kutlubay Z, et al. Validation of the Behçet's Syndrome Overall Damage Index (BODI) for retrospective studies and a proposal for modification. *Rheumatology (Oxford)*. 2024.
 8. Wang N, Xie Y, Wang Z. Two cases of Behcet's disease-like syndrome with gene deficiency in ELF4. *Sichuan Da Xue Xue Bao Yi Xue Ban*. 2024; 55(3): 756–61.
 9. Yilmaz Çakmak N, Ata N, Güven SC, Gemcioğlu E, Ülgü MM, Birinci Ş. Impact of celiac disease in Behçet's syndrome patients: a study based on the database of Türkiye. *Turk J Med Sci*. 2024; 54(3): 493–501.
 10. Qu W, Chen Y, Zhang Z. Behçet's syndrome masquerading as infective endocarditis: a diagnostic conundrum and therapeutic challenge. *Cardiovasc Pathol*. 2024; 71(107648): 107648.
 11. Hu D, She C-H, Bao H-F, Zou J, Cai J-F, Ye J-F, et al. Clinical heterogeneity and five phenotypes identified in pediatric Behçet's syndrome: a cohort study from Shanghai Behçet's syndrome database. *World J Pediatr*. 2024; 20(8): 801–8.
 12. Almutamaiz AH, Alshoabi SA, Al Akhali ES, Hamid AM, Gareeballah A, Omer AM. Behçet's syndrome with multiple bilateral pulmonary aneurysms associated with endomyocardial fibrosis presented with pulmonary emboli: a case report. *Cureus*. 2024; 16(8): e66281.
 13. Kechida M, Bazewicz M, Nabi W, Daadaa S, Willermann F, Abroug N, et al. Recent advances in the diagnosis and management of Behçet's syndrome uveitis. *Expert Rev Ophthalmol*. 2024; 1–20.
 14. Esatoglu SN, Sonmez O, Ucar D, Kaymaz E, Ozguler Y, Ugurlu S, et al. *De novo* manifestations during adalimumab treatment in Behçet's syndrome. *Rheumatology (Oxford)*. 2024.
 15. Ekici M, İleri S, Ünaldı E, Bayram GSK, Kılıç L, Akdoğan A. Are Behçet's disease patients with Budd-Chiari syndrome at increased risk for the development of pulmonary hypertension? *Rheumatology (Oxford)*. 2024; 63(9): e248–50.
 16. Di Cianni F, Mastrolia MV, Biancalana E, Marinello D, Emmi G, Mosca M, et al. Challenges and opportunities in transitional care process in Behçet's syndrome. *Front Med (Lausanne)*. 2024; 11: 1456063.
 17. Ez-Zaky S, Laasri I, Jroundi L, Laamrani FZ. Dyspnea and hemoptysis revealing Behçet's syndrome: Pulmonary artery aneurysms in a case report. *Radiol Case Rep*. 2025; 20(1): 115–8.
 18. Park J-B, Han SJ, Lee SB, Kim DH, Cheon JH, Hwang SW, et al. Optimal treatment approaches to intestinal Behçet's disease complicated by myelodysplastic syndrome: The KASID and KSBD multicenter study. *Yonsei Med J*. 2024; 65(5): 265–75.
 19. Ozguler Y, Merkel PA, Gurcan M, Bocage C, Eriksen W, Kutlubay Z, et al. Patients' experiences with Behçet's syndrome: structured interviews among patients with different types of organ involvement. *Clin Exp Rheumatol*. 2019; 37 Suppl 121(6): 28–34.
 20. Hatemi G, Meara A, Özgüler Y, Direskeneli H, Mahr A, Shea B, et al. Core set of domains for Outcome Measures in Behçet's syndrome. *Arthritis Care Res (Hoboken)*. 2022; 74(4): 691–9.